Clinical Commissioning Policy: Rituximab for second line treatment for anti-NMDAR autoimmune encephalitis (all ages)

Document first published:
Page updated:
Topic:
,
Publication type:

This policy document outlines the arrangements for funding of Rituximab for second line treatment for anti-NMDAR autoimmune encephalitis (all ages).